Michael Weyand
Research Subjects
Michael Weyand has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Clemens Steegborn
Department of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany
3 shared publications - Frank Harig
Department of Cardiac Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany
3 shared publications - Christian Heim
Department of Cardiac Surgery, University Hospital Erlangen, Erlangen, Germany
2 shared publications Ehab Nooh
Department of Cardiac Surgery, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
2 shared publications- Joachim Schmidt
Department of Thoracic Surgery , Helios Hospital Bonn/Rhein-Sieg , Bonn , Germany
2 shared publications Markus Kondruweit
Department of Cardiac Surgery, Universitätsklinikum Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 82 (1) , 32-40
Potential 14-3-3 binding sites in sirtuins reveal extended phosphosite-recognition modes
The adapter proteins of the 14-3-3 family modulate the activity and/or localization of their binding partners, which they capture if a generic target motif is in its phosphorylated state. Here, we report the identification of potential 14-3-3 binding sites in human sirtuin deacylases by bioinformatic analysis. We then characterize the interactions of peptides representing phosphorylation sites in sirtuin 3 (pS103) and sirtuin 1 (pS670) with 14-3-3 proteins. We further describe the crystal structures of complexes of 14-3-3σ with either of the two phosphopeptides. As a conclusion, we propose a more extended 14-3-3 binding mode on the N-terminal side of the phosphorylation site and the possibility of nongeneric motifs and conformations on the C-terminal side, still resulting in the known high binding affinity of the two partners.
- 1 January 2026
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 82 (1) , 32-40
Open AccessPotential 14-3-3 binding sites in sirtuins reveal extended phosphosite-recognition modes
The adapter proteins of the 14-3-3 family modulate the activity and/or localization of their binding partners, which they capture if a generic target motif is in its phosphorylated state. Here, we report the identification of potential 14-3-3 binding sites in human sirtuin deacylases by bioinformatic analysis. We then characterize the interactions of peptides representing phosphorylation sites in sirtuin 3 (pS103) and sirtuin 1 (pS670) with 14-3-3 proteins. We further describe the crystal structures of complexes of 14-3-3σ with either of the two phosphopeptides. As a conclusion, we propose a more extended 14-3-3 binding mode on the N-terminal side of the phosphorylation site and the possibility of nongeneric motifs and conformations on the C-terminal side, still resulting in the known high binding affinity of the two partners.
- Open Access
Molecular Mechanism of Sirtuin 1 Inhibition by Human Immunodeficiency Virus 1 Tat Protein
Sirtuins are NAD+-dependent protein lysine deacylases implicated in metabolic regulation and aging-related dysfunctions. The nuclear isoform Sirt1 deacetylates histones and transcription factors and contributes, e.g., to brain and immune cell functions. Upon infection by human immunodeficiency virus 1 (HIV1), Sirt1 deacetylates the viral transactivator of transcription (Tat) protein to promote the expression of the viral genome. Tat, in turn, inhibits Sirt1, leading to the T cell hyperactivation associated with HIV infection. Here, we describe the molecular mechanism of Tat-dependent sirtuin inhibition. Using Tat-derived peptides and recombinant Tat protein, we mapped the inhibitory activity to Tat residues 34–59, comprising Tat core and basic regions and including the Sirt1 deacetylation site Lys50. Tat binds to the sirtuin catalytic core and inhibits Sirt1, Sirt2, and Sirt3 with comparable potencies. Biochemical data and crystal structures of sirtuin complexes with Tat peptides reveal that Tat exploits its intrinsically extended basic region for binding to the sirtuin substrate binding cleft through substrate-like β-strand interactions, supported by charge complementarity. Tat Lys50 is positioned in the sirtuin substrate lysine pocket, although binding and inhibition do not require prior acetylation and rely on subtle differences to the binding of regular substrates. Our results provide mechanistic insights into sirtuin regulation by Tat, improving our understanding of physiological sirtuin regulation and the role of this interaction during HIV1 infection.
Open AccessMolecular Mechanism of Sirtuin 1 Inhibition by Human Immunodeficiency Virus 1 Tat Protein
Sirtuins are NAD+-dependent protein lysine deacylases implicated in metabolic regulation and aging-related dysfunctions. The nuclear isoform Sirt1 deacetylates histones and transcription factors and contributes, e.g., to brain and immune cell functions. Upon infection by human immunodeficiency virus 1 (HIV1), Sirt1 deacetylates the viral transactivator of transcription (Tat) protein to promote the expression of the viral genome. Tat, in turn, inhibits Sirt1, leading to the T cell hyperactivation associated with HIV infection. Here, we describe the molecular mechanism of Tat-dependent sirtuin inhibition. Using Tat-derived peptides and recombinant Tat protein, we mapped the inhibitory activity to Tat residues 34–59, comprising Tat core and basic regions and including the Sirt1 deacetylation site Lys50. Tat binds to the sirtuin catalytic core and inhibits Sirt1, Sirt2, and Sirt3 with comparable potencies. Biochemical data and crystal structures of sirtuin complexes with Tat peptides reveal that Tat exploits its intrinsically extended basic region for binding to the sirtuin substrate binding cleft through substrate-like β-strand interactions, supported by charge complementarity. Tat Lys50 is positioned in the sirtuin substrate lysine pocket, although binding and inhibition do not require prior acetylation and rely on subtle differences to the binding of regular substrates. Our results provide mechanistic insights into sirtuin regulation by Tat, improving our understanding of physiological sirtuin regulation and the role of this interaction during HIV1 infection.
- Open Access
- 24 August 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon Reports
- Vol. 11 (01) , e50-e53
Dysphonia as a Presenting Symptom of a Giant Left Atrial Sarcoma Developing within Five Years
An 83-year-old woman presented with a new onset of dyspnea and dysphonia. Physical examination revealed no abnormalities. Computerized tomography, bidimensional echocardiography, and cardiac magnetic resonance confirmed the presence of a cardiac mass in the left atrium. Surgical resection was uneventful and showed the origin of the mass in the ostium of the left inferior pulmonary vein. Histological evaluation revealed undifferentiated pleomorphic sarcoma with myxoid features. This case highlights the importance of considering cardiac neoplasms as a rare differential diagnosis, including rare and misleading clinical presentations.
- 24 August 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon Reports
- Vol. 11 (01) , e50-e53
Open AccessDysphonia as a Presenting Symptom of a Giant Left Atrial Sarcoma Developing within Five Years
An 83-year-old woman presented with a new onset of dyspnea and dysphonia. Physical examination revealed no abnormalities. Computerized tomography, bidimensional echocardiography, and cardiac magnetic resonance confirmed the presence of a cardiac mass in the left atrium. Surgical resection was uneventful and showed the origin of the mass in the ostium of the left inferior pulmonary vein. Histological evaluation revealed undifferentiated pleomorphic sarcoma with myxoid features. This case highlights the importance of considering cardiac neoplasms as a rare differential diagnosis, including rare and misleading clinical presentations.
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 01) , S1-S61
Prophylactic Implantation of Intra-aortic Balloon Counterpulsation in High-Risk Cardiac Surgery Patients: A Single-Center Experience
Background: Intra-aortic balloon pump (IABP) is a controversially discussed option to treat patients with heart failure. The overall impact and hereby also the prophylactic implantation of an IABP have decreased in recent years, but is still part of surgical practice. Therefore, the aim of this study was to investigate prophylactic implantation of an IABP on the outcome of high-risk patients from a single center. Method: We analyzed a total of 487 patients from 2007 to 2020 with indication for surgical revascularization and highly reduced ejection fraction < 30%. 285 of them received preoperative IABP implantation. Patients were analyzed, assessing gender, risk profile, preoperative ejection fraction (EF), and complication rates in terms of mechanical circulatory support or 30-day mortality. Results: Overall 30-day mortality was comparable in group 1 with preoperative IABP compared with group 2 without preoperative IABP (20.7 vs. 15.3%; n.s.). Mean age was 65.8 ± 9.5 (group 1) versus 65 ± 10.4 years (group 2; p = 0.37) with 84.2% male in group 1 versus 81.2% male in group 2. Mean EuroSCORE 2 was comparable in group 1 (9.95) compared with 9.75 in group 2 (p = 0.59). Rate of cardiogenic shock patients was slightly elevated in group 2 (19.8 vs. 17.2%) but did not reach statistical significance. Pre-op ejection fraction was not significantly different in both groups (21.5 vs. 22.2%; p = 0.23). However, perioperative requirement of VA-ECMO (group 1: 1.4% vs. group 2: 5.4%; p = 0.01) and switch to durable MCS (group 1: 7.4% vs. group 2: 23.8%; p < 0.01) was significantly different in both groups, while 30-day mortality was statistically not different (group 1: 20.7% vs. group 2:15.4%; p = 0.13). Conclusion: Our analysis demonstrates that IABP support in high-risk patients may be an effective way to treat patients with reduced LV function preoperatively. The significant better results in terms of MCS support may also be attributed to a selection bias and a slightly higher rate of cardiogenic shock patients in the no-IABP group, which ultimately may have driven surgeons to a more definitive surgical strategy with VAD implantation instead of high risk CABG. The prophylactic implantation of IABP should still be taken into account and should consider clinical conditions. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 01) , S1-S61
Prophylactic Implantation of Intra-aortic Balloon Counterpulsation in High-Risk Cardiac Surgery Patients: A Single-Center Experience
Background: Intra-aortic balloon pump (IABP) is a controversially discussed option to treat patients with heart failure. The overall impact and hereby also the prophylactic implantation of an IABP have decreased in recent years, but is still part of surgical practice. Therefore, the aim of this study was to investigate prophylactic implantation of an IABP on the outcome of high-risk patients from a single center. Method: We analyzed a total of 487 patients from 2007 to 2020 with indication for surgical revascularization and highly reduced ejection fraction < 30%. 285 of them received preoperative IABP implantation. Patients were analyzed, assessing gender, risk profile, preoperative ejection fraction (EF), and complication rates in terms of mechanical circulatory support or 30-day mortality. Results: Overall 30-day mortality was comparable in group 1 with preoperative IABP compared with group 2 without preoperative IABP (20.7 vs. 15.3%; n.s.). Mean age was 65.8 ± 9.5 (group 1) versus 65 ± 10.4 years (group 2; p = 0.37) with 84.2% male in group 1 versus 81.2% male in group 2. Mean EuroSCORE 2 was comparable in group 1 (9.95) compared with 9.75 in group 2 (p = 0.59). Rate of cardiogenic shock patients was slightly elevated in group 2 (19.8 vs. 17.2%) but did not reach statistical significance. Pre-op ejection fraction was not significantly different in both groups (21.5 vs. 22.2%; p = 0.23). However, perioperative requirement of VA-ECMO (group 1: 1.4% vs. group 2: 5.4%; p = 0.01) and switch to durable MCS (group 1: 7.4% vs. group 2: 23.8%; p < 0.01) was significantly different in both groups, while 30-day mortality was statistically not different (group 1: 20.7% vs. group 2:15.4%; p = 0.13). Conclusion: Our analysis demonstrates that IABP support in high-risk patients may be an effective way to treat patients with reduced LV function preoperatively. The significant better results in terms of MCS support may also be attributed to a selection bias and a slightly higher rate of cardiogenic shock patients in the no-IABP group, which ultimately may have driven surgeons to a more definitive surgical strategy with VAD implantation instead of high risk CABG. The prophylactic implantation of IABP should still be taken into account and should consider clinical conditions. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 01) , S1-S61
Wearable Cardioverter Defibrillator (WCD) after Cardiac Surgery
Background: Patients with left ventricular ejection fraction (LVEF) < 35% are at high risk of sudden cardiac death (SCD) and benefit from implantable cardioverter-defibrillator (ICD) therapy. ICD implantation is not favorable during the first 40 days after acute myocardial infarction and < 3 months after coronary artery bypass grafting because of the chances of cardiac recovery. The cardioverter defibrillator jacket is a therapy option for preventing sudden cardiac death in this bridging phase and as distention therapy in case of myocardium recovery. This study evaluated the effectiveness of cardioverter-defibrillator jacket after cardiac surgery. Method: This is a retrospective study conducted in the Heart Center of Erlangen from 2018 to 2021. Forty-eight patients who had wearable cardioverter-defibrillator (WCD) were retrospectively analyzed and followed up. Patient's demographics, defibrillation treatments, and periods of wearing the jacket through the day for every patient were retrospectively obtained from the manufacturer company database. The patients were examined if they had to get implanted ICD at the end of the follow-up after therapy. Results: Forty-eight patients (mean age: 64) (92% men and 8% women) were treated with a WCD in response to heart failure (mean EF: 26%) after cardiac surgery (ICM: 44 patients, NICM: 4 patients). Average daily use of a WCD was 22.2 hours in a day per patient which were worn for average 61 days. At that time, a median of 7 events were detected but not treated, 2 defibrillations performed, and no asystole seen. After a follow-up of 3 months, patients asked to come to our outpatient clinic for a new evaluation of cardiac myocardial function based on clinical examination and echocardiography assessment of the ejection fraction. At the end of the follow-up all patients were alive. 57% (n = 27) of the patients showed recovery of the ejection fraction and had a freedom from implantation of an ICD. 31% (n = 15) of the patients have to be admitted from implantation of an ICD, 12% (n = 6) of the patients are lost in follow-up. Conclusion: A wearable cardioverter defibrillator is an effective alternative for prevention of sudden cardiac death during myocardium recovery period after a cardiac Surgery. It is worth knowing that defibrillator jacket can save health care system resources when it used as a bridging therapy until the cardiac function recovered. Health care providers must know that this treatment required a high patient compliance. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 01) , S1-S61
Wearable Cardioverter Defibrillator (WCD) after Cardiac Surgery
Background: Patients with left ventricular ejection fraction (LVEF) < 35% are at high risk of sudden cardiac death (SCD) and benefit from implantable cardioverter-defibrillator (ICD) therapy. ICD implantation is not favorable during the first 40 days after acute myocardial infarction and < 3 months after coronary artery bypass grafting because of the chances of cardiac recovery. The cardioverter defibrillator jacket is a therapy option for preventing sudden cardiac death in this bridging phase and as distention therapy in case of myocardium recovery. This study evaluated the effectiveness of cardioverter-defibrillator jacket after cardiac surgery. Method: This is a retrospective study conducted in the Heart Center of Erlangen from 2018 to 2021. Forty-eight patients who had wearable cardioverter-defibrillator (WCD) were retrospectively analyzed and followed up. Patient's demographics, defibrillation treatments, and periods of wearing the jacket through the day for every patient were retrospectively obtained from the manufacturer company database. The patients were examined if they had to get implanted ICD at the end of the follow-up after therapy. Results: Forty-eight patients (mean age: 64) (92% men and 8% women) were treated with a WCD in response to heart failure (mean EF: 26%) after cardiac surgery (ICM: 44 patients, NICM: 4 patients). Average daily use of a WCD was 22.2 hours in a day per patient which were worn for average 61 days. At that time, a median of 7 events were detected but not treated, 2 defibrillations performed, and no asystole seen. After a follow-up of 3 months, patients asked to come to our outpatient clinic for a new evaluation of cardiac myocardial function based on clinical examination and echocardiography assessment of the ejection fraction. At the end of the follow-up all patients were alive. 57% (n = 27) of the patients showed recovery of the ejection fraction and had a freedom from implantation of an ICD. 31% (n = 15) of the patients have to be admitted from implantation of an ICD, 12% (n = 6) of the patients are lost in follow-up. Conclusion: A wearable cardioverter defibrillator is an effective alternative for prevention of sudden cardiac death during myocardium recovery period after a cardiac Surgery. It is worth knowing that defibrillator jacket can save health care system resources when it used as a bridging therapy until the cardiac function recovered. Health care providers must know that this treatment required a high patient compliance. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 December 2021
- Published by S. Karger AG in European Surgical Research
- Vol. 63 (2) , 98-104
Pass On What You Have Learned: A Structured Mentor-Mentee Concept for the Implementation of a Minimally Invasive Mitral Valve Surgery Program
Introduction: Starting a minimally invasive cardiac surgery (MICS) for mitral valve repair (MVR) program is challenging as it requires a new learning curve, but compromising surgical results at the same time is not acceptable. Here, we describe our surgical educational experience of starting a new MICS program at a university heart center in Germany. Methods: A dedicated team for the new MICS program including 2 cardiac surgeons, 1 cardiac anesthetist, 1 perfusionist, and 1 scrub nurse was chosen. The use of long shafted instruments was trained in a low-cost self-assembled MICS simulator, and the EACTS endoscopic dry lab course was visited. Thereafter, 1 MICS center was visited for direct observation and peer-to-peer education for 6 weeks. The mentor observed the first 10 cases performed by the mentee. The surgical mitral valve expertise of 1 single cardiac surgeon was retrospectively analyzed between April 2016 and April 2021. Results: Before the implementation of the MICS-MVR program, 18 mitral valve operations have been performed through sternotomy between April 2016 and October 2018 including 12 replacements and 6 ring annuloplasties. After starting the MICS-MVR program, 73 mitral operations have been performed by the same surgeon of which 53 video-assisted through minithoracotomy (72.6%). 83.1% of the MICS procedures included complex repair (n = 38) and ring annuloplasty (n = 6). Open heart MV surgery was necessary in 20 patients due to concomitant procedures (n = 8), redo procedures (n = 2), severe endocarditis (n = 4), or contraindication for MICS such as PAD (n = 6). There have been no deaths, 1 stroke, and 1 cardiac vascular (RCX) complication. Two patients required conversion to sternotomy and one pericardiocentesis in the long term. Conclusion: Typically, excellent exposure and high repair rates of the MV has led us offer MICS approach to a majority of patients with isolated MV disease. Careful planning and a strict mentor-mentee concept facilitated a safe startup of an MICS program in a busy university heart center.
- 1 December 2021
- Published by S. Karger AG in European Surgical Research
- Vol. 63 (2) , 98-104
Pass On What You Have Learned: A Structured Mentor-Mentee Concept for the Implementation of a Minimally Invasive Mitral Valve Surgery Program
Introduction: Starting a minimally invasive cardiac surgery (MICS) for mitral valve repair (MVR) program is challenging as it requires a new learning curve, but compromising surgical results at the same time is not acceptable. Here, we describe our surgical educational experience of starting a new MICS program at a university heart center in Germany. Methods: A dedicated team for the new MICS program including 2 cardiac surgeons, 1 cardiac anesthetist, 1 perfusionist, and 1 scrub nurse was chosen. The use of long shafted instruments was trained in a low-cost self-assembled MICS simulator, and the EACTS endoscopic dry lab course was visited. Thereafter, 1 MICS center was visited for direct observation and peer-to-peer education for 6 weeks. The mentor observed the first 10 cases performed by the mentee. The surgical mitral valve expertise of 1 single cardiac surgeon was retrospectively analyzed between April 2016 and April 2021. Results: Before the implementation of the MICS-MVR program, 18 mitral valve operations have been performed through sternotomy between April 2016 and October 2018 including 12 replacements and 6 ring annuloplasties. After starting the MICS-MVR program, 73 mitral operations have been performed by the same surgeon of which 53 video-assisted through minithoracotomy (72.6%). 83.1% of the MICS procedures included complex repair (n = 38) and ring annuloplasty (n = 6). Open heart MV surgery was necessary in 20 patients due to concomitant procedures (n = 8), redo procedures (n = 2), severe endocarditis (n = 4), or contraindication for MICS such as PAD (n = 6). There have been no deaths, 1 stroke, and 1 cardiac vascular (RCX) complication. Two patients required conversion to sternotomy and one pericardiocentesis in the long term. Conclusion: Typically, excellent exposure and high repair rates of the MV has led us offer MICS approach to a majority of patients with isolated MV disease. Careful planning and a strict mentor-mentee concept facilitated a safe startup of an MICS program in a busy university heart center.
- Open Access
- 1 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2055, 140005
Developing a patient individualized flexible silicone implant using SLS and vacuum die casting
- 1 January 2019
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2055, 140005
Open AccessDeveloping a patient individualized flexible silicone implant using SLS and vacuum die casting
- 17 July 2013
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 69 (8) , 1423-1432
Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+and SRT1720: binding details and inhibition mechanism
Sirtuins are NAD(+)-dependent protein deacetylases that regulate metabolism and aging processes and are considered to be attractive therapeutic targets. Most available sirtuin modulators are little understood mechanistically, hindering their improvement. SRT1720 was initially described as an activator of human Sirt1, but it also potently inhibits human Sirt3. Here, the molecular mechanism of the inhibition of Sirt3 by SRT1720 is described. A crystal structure of Sirt3 in complex with SRT1720 and an NAD(+) analogue reveals that the compound partially occupies the acetyl-Lys binding site, thus explaining the reported competition with the peptide substrate. The compound packs against a hydrophobic protein patch and binds with its opposite surface to the NAD(+) nicotinamide, resulting in an exceptionally tight sandwich-like interaction. The observed arrangement rationalizes the uncompetitive inhibition with NAD(+), and binding measurements confirm that the nicotinamide moiety of NAD(+) supports inhibitor binding. Consistently, no inhibitor is bound in a second crystal structure of Sirt3 that was solved complexed with ADP-ribose and crystallized in the presence of SRT1720. These results reveal a novel sirtuin inhibitor binding site and mechanism, and provide a structural basis for compound improvement.
- 17 July 2013
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 69 (8) , 1423-1432
Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+and SRT1720: binding details and inhibition mechanism
Sirtuins are NAD(+)-dependent protein deacetylases that regulate metabolism and aging processes and are considered to be attractive therapeutic targets. Most available sirtuin modulators are little understood mechanistically, hindering their improvement. SRT1720 was initially described as an activator of human Sirt1, but it also potently inhibits human Sirt3. Here, the molecular mechanism of the inhibition of Sirt3 by SRT1720 is described. A crystal structure of Sirt3 in complex with SRT1720 and an NAD(+) analogue reveals that the compound partially occupies the acetyl-Lys binding site, thus explaining the reported competition with the peptide substrate. The compound packs against a hydrophobic protein patch and binds with its opposite surface to the NAD(+) nicotinamide, resulting in an exceptionally tight sandwich-like interaction. The observed arrangement rationalizes the uncompetitive inhibition with NAD(+), and binding measurements confirm that the nicotinamide moiety of NAD(+) supports inhibitor binding. Consistently, no inhibitor is bound in a second crystal structure of Sirt3 that was solved complexed with ADP-ribose and crystallized in the presence of SRT1720. These results reveal a novel sirtuin inhibitor binding site and mechanism, and provide a structural basis for compound improvement.
- 1 August 2012
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 130 (2) , 265e-273e
Immunohistochemical Evaluation after Ex Vivo Perfusion of Rectus Abdominis Muscle Flaps in a Porcine Model
The purpose of this study was to investigate whether and how the extracorporal perfusion of muscle flaps with a miniaturized perfusion system could change the expression of the proapoptotic protein caspase 3 and of the ischemia-sensitive protein hypoxia-inducible factor (HIF)-1α as a first step toward the development of a clinically reliable tool for circumventing ischemia problems in free muscle flap transfer. In this study, 25 porcine rectus abdominis muscles were used and assigned to five different groups. In the baseline group (group I), the muscle flap remained in situ; in groups II and III, the muscle flap was harvested and remained ex vivo without or with subsequent single-shot heparinized flush; and in groups IV and V, the flaps were perfused with either heparinized autologous whole blood or crystalloid fluid (Jonosteril), using a miniaturized perfusion system without Exogen oxygenation. Muscle samples were taken for immunohistochemical evaluation. The proportion of positive cells for HIF-1α and caspase 3 was compared for each group (groups II through V) to the baseline group (group I). The expression of HIF-1α and caspase 3 was increased in both groups without perfusion and was low during in vivo perfusion and extracorporal perfusion with crystalloid fluid. Heparinized autologous whole blood perfusion shows no protective effect, in contrast to the crystalloid fluid. The data of this study indicate that the extracorporal perfusion of muscle flaps with crystalloid fluid is a possible protective strategy against ischemia. Autologous heparinized whole blood seems to have no additional protective effect in a pure perfusion setting without oxygenation.
- 1 August 2012
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 130 (2) , 265e-273e
Immunohistochemical Evaluation after Ex Vivo Perfusion of Rectus Abdominis Muscle Flaps in a Porcine Model
The purpose of this study was to investigate whether and how the extracorporal perfusion of muscle flaps with a miniaturized perfusion system could change the expression of the proapoptotic protein caspase 3 and of the ischemia-sensitive protein hypoxia-inducible factor (HIF)-1α as a first step toward the development of a clinically reliable tool for circumventing ischemia problems in free muscle flap transfer. In this study, 25 porcine rectus abdominis muscles were used and assigned to five different groups. In the baseline group (group I), the muscle flap remained in situ; in groups II and III, the muscle flap was harvested and remained ex vivo without or with subsequent single-shot heparinized flush; and in groups IV and V, the flaps were perfused with either heparinized autologous whole blood or crystalloid fluid (Jonosteril), using a miniaturized perfusion system without Exogen oxygenation. Muscle samples were taken for immunohistochemical evaluation. The proportion of positive cells for HIF-1α and caspase 3 was compared for each group (groups II through V) to the baseline group (group I). The expression of HIF-1α and caspase 3 was increased in both groups without perfusion and was low during in vivo perfusion and extracorporal perfusion with crystalloid fluid. Heparinized autologous whole blood perfusion shows no protective effect, in contrast to the crystalloid fluid. The data of this study indicate that the extracorporal perfusion of muscle flaps with crystalloid fluid is a possible protective strategy against ischemia. Autologous heparinized whole blood seems to have no additional protective effect in a pure perfusion setting without oxygenation.
- 1 July 2008
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 136 (1) , 213-214
Early failure of a mechanical bileaflet aortic valve prosthesis due to pannus: A rare complication
- 1 July 2008
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 136 (1) , 213-214
Early failure of a mechanical bileaflet aortic valve prosthesis due to pannus: A rare complication